. 2021 Sep 24;101(1):69–79. doi: 10.1007/s00277-021-04644-3

Table 2.

Clinical and lab characteristics of COVID-19 in haematological cases

Variable	All pts (n = 242)	Mild COVID (n = 153)	Moderate/severe COVID (n = 89)	p value
Age, years Median (range)	41(3–83)	27.5(3–76)	56(4–83)	0.018
Type of haematological cancer; N (%)
Acute myeloid leukaemia Acute lymphoblastic leukaemia Non-Hodgkin’s lymphoma Hodgkin’s lymphoma Multiple myeloma Chronic myeloid leukaemia CLL Post stem cell transplant	32(13.2) 83(35.2) 46(19) 4(1.7) 34(14.9) 24(9.9) 11(2.8) 8(3.3)	24(75) 65(78.9) 16(33.3) 3(75) 22(66.6) 19(80) 2(28.5) 2(25)	8(25) 18(21.1) 30(66.7) 1(25) 12(33.4) 5(20) 9(71.5) 6(75)	0.12 0.07 0.23 0.17 0.09 0.10 0.11 0.32
Duration of COVID symptoms; N (%)
< 7 days ≥ 7 days	84(34.7) 158(65.3)	60(85.7) 93(54)	24 (34.3) 65 (37.8)	0.001
Time from last chemotherapy for haematological malignancy
< 4 weeks > 4 weeks	116(47.9) 126(52.1)	73(62) 80(63.5)	43 (48.3) 46(51.7)	0.844
Status of haematological malignancy at COVID-19 diagnosis; N (%)
Remission Active disease	94(38.8) 148(61.2)	78(83.0) 75(50.7)	16(17) 73(49.3)	0.009
Laboratory findings, median (IQR)
WBC (cells/µl) Neutrophils (cells/µl) NLR Absolute lymphocyte count (cells/µl) Platelets (cells/µl) Hb (gm%) D-dimer Procalcitonin CRP Serum ferritin (ng/ml) Serum fibrinogen	5800(2925–10,625) 2150(1275–5550) 2.5(1.063–5.583) 1500(1200–4800) 116(42,000–1.64) 9.25(7.72–10.47) 368(221–887.5) 0.21(0.08–1.235) 17.5(10.25–41.75) 452(295–1446) 324(280–420)	5350(2625–-8975) 3150(1425–5800) 2.36(1.31–4.55) 2100(1600–4800) 135(48.5–1.80) 9.6(8.6–10.32) 287(190.75–666.75) 0.12(0.06–0.30) 12.5(9.5–24.25) 342(267–551.25) 300(268.7–380)	8250(3000–33,825) 2100(1150–5450) 3.46(0.488–22.125) 1100(900–2100) 89(27–140) 8.25(6.87–10.55) 765(338.5–1900) 3.37(0.23–7.185) 46.5(22.75–130) 1700(577–3712) 393(321–472.5)	0.163 0.645 0.591 0.04 0.093 0.177 0.001 0.001 0.005 0.02 0.09
Coexisting co-morbidity(total); N (%)
Cardiovascular disease Pulmonary disease Connective tissue Liver disease Kidney disease Diabetes Non-haematological cancers	68(28.1) 38(15.7) 12(4.9) 4(1.6) 32(13.2) 51(21.1) 04(1.6)	28(41.2) 23(60.5) 10(83.3) 2(50) 16(50) 15(38.5) 01(25)	40(58.8) 15(39.5) 2(16.7) 2(50) 16(50) 36(61.5) 03 (75)	0.07 0.216 0.985 0.612 0.475 0.046 0.443
Blood group
A B AB O	86 (35.5) 84(34.7) 21(8.7) 51(21.1)	55(64.0) 52(61.9) 13(61.9) 33(64.7)	31(36.0) 32(38.1) 08(38.1) 18(35.3)	0.09 0.14 0.12 0.11

Variable

All pts
(n = 242)

Mild COVID (n = 153)

Moderate/severe COVID (n = 89)

p value

Age, years

Median (range)

41(3–83)

27.5(3–76)

56(4–83)

0.018

Type of haematological cancer; N (%)

Acute myeloid leukaemia

Acute lymphoblastic leukaemia

Non-Hodgkin’s lymphoma

Hodgkin’s lymphoma

Multiple myeloma

Chronic myeloid leukaemia

CLL

Post stem cell transplant

32(13.2)

83(35.2)

46(19)

4(1.7)

34(14.9)

24(9.9)

11(2.8)

8(3.3)

24(75)

65(78.9)

16(33.3)

3(75)

22(66.6)

19(80)

2(28.5)

2(25)

8(25)

18(21.1)

30(66.7)

1(25)

12(33.4)

5(20)

9(71.5)

6(75)

0.12

0.07

0.23

0.17

0.09

0.10

0.11

0.32

Duration of COVID symptoms; N (%)

< 7 days

≥ 7 days

84(34.7)

158(65.3)

60(85.7)

93(54)

24 (34.3)

65 (37.8)

0.001

Time from last chemotherapy for haematological malignancy

< 4 weeks

> 4 weeks

116(47.9)

126(52.1)

73(62)

80(63.5)

43 (48.3)

46(51.7)

0.844

Status of haematological malignancy at COVID-19 diagnosis; N (%)

Remission

Active disease

94(38.8)

148(61.2)

78(83.0)

75(50.7)

16(17)

73(49.3)

0.009

Laboratory findings, median (IQR)

WBC (cells/µl)

Neutrophils (cells/µl)

NLR

Absolute lymphocyte count (cells/µl)

Platelets (cells/µl)

Hb (gm%)

D-dimer

Procalcitonin

CRP

Serum ferritin (ng/ml)

Serum fibrinogen

5800(2925–10,625)

2150(1275–5550)

2.5(1.063–5.583)

1500(1200–4800)

116(42,000–1.64)

9.25(7.72–10.47)

368(221–887.5)

0.21(0.08–1.235)

17.5(10.25–41.75)

452(295–1446)

324(280–420)

5350(2625–-8975)

3150(1425–5800)

2.36(1.31–4.55)

2100(1600–4800)

135(48.5–1.80)

9.6(8.6–10.32)

287(190.75–666.75)

0.12(0.06–0.30)

12.5(9.5–24.25)

342(267–551.25)

300(268.7–380)

8250(3000–33,825)

2100(1150–5450)

3.46(0.488–22.125)

1100(900–2100)

89(27–140)

8.25(6.87–10.55)

765(338.5–1900)

3.37(0.23–7.185)

46.5(22.75–130)

1700(577–3712)

393(321–472.5)

0.163

0.645

0.591

0.04

0.093

0.177

0.001

0.005

0.02

0.09

Coexisting co-morbidity(total); N (%)

Cardiovascular disease

Pulmonary disease

Connective tissue

Liver disease

Kidney disease

Diabetes

Non-haematological cancers

68(28.1)

38(15.7)

12(4.9)

4(1.6)

32(13.2)

51(21.1)

04(1.6)

28(41.2)

23(60.5)

10(83.3)

2(50)

16(50)

15(38.5)

01(25)

40(58.8)

15(39.5)

2(16.7)

2(50)

16(50)

36(61.5)

03 (75)

0.07

0.216

0.985

0.612

0.475

0.046

0.443

Blood group

86 (35.5)

84(34.7)

21(8.7)

51(21.1)

55(64.0)

52(61.9)

13(61.9)

33(64.7)

31(36.0)

32(38.1)

08(38.1)

18(35.3)

0.09

0.14

0.12

0.11